Chang Xu

Employment

• Foundation Medicine Associate Director
  2020 - Present
• QIAGEN Associate Principal Statistician
  2019 - 2020
• QIAGEN Senior Biostatistician
  2015 - 2019

Education

• University of Missouri Columbia PhD
  2006 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (47)

• Supplementary Table S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013664
  +Save
• Supplementary Figure S6 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013676
  +Save
• Supplementary Figure S7 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013673.v1
  +Save
• Supplementary Figure S7 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013673
  +Save
• Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013670.v1
  +Save
• Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013670
  +Save
• Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013667.v1
  +Save
• Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013667
  +Save
• Supplementary Table S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.27013664.v1
  +Save
• Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
  2024 DOI: 10.1158/1078-0432.c.7447775.v1
  +Save